Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms

N/AActive Not RecruitingNCT06731946

Yibin Fang150 enrolled

Overview

This study aims to retrospectively evaluate the efficacy and safety of the Surpass Evolve Flow Diverter in treating complex intracranial aneurysms. It seeks to assess long-term outcomes and complication rates while analyzing the impact of patient characteristics and aneurysm types on treatment effectiveness. By collecting data from multiple centers, the study ensures broad representativeness, ultimately providing valuable insights for clinical management on a global scale.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Intracranial Arterial Aneurysm

Interventions

Flow divertingDEVICE

Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥ 18 years with a confirmed diagnosis of intracranial aneurysm. 2. Imaging studies confirming suitability for Surpass Evolve Flow Diverter treatment. 3. Aneurysms meeting flow diverter treatment indications (e.g., aneurysms larger than 4 mm). 4. At least six months of follow-up data available post-treatment. Exclusion Criteria: 1. Patients with acutely ruptured aneurysms or significant bleeding. 2. Patients with incomplete data or insufficient follow-up records.

Locations (1)

Shanghai Fourth People's Hospital

Shanghai, China